EUVIMEDEUVIMED entdecken
Multizentrische Studie

6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy

Natalie Yu iD, Tanya Lee, Daniel Tassone iD, Sara Vogrin, Steven Phan, Damien M Wu, Jason Zhang, Luke Wang, Jason Tjahyadi, Krishneel Dutt, Hana Liou, Chamara Basnayake iD und 15 weitere

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16504 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Natalie Yu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Adalimumab, Drug Therapy, Combination, Inflammatory Bowel Diseases, Infliximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thiopurine co‐therapy with anti‐tumour necrosis factor‐alpha (anti‐TNFα) agents is associated with higher anti‐TNFα drug levels and reduced immunogenicity in inflammatory bowel disease (IBD).

Aims

We aimed to evaluate the association between 6‐thioguanine nucleotide (6‐TGN) and anti‐TNFα levels and the optimal 6‐TGN threshold level associated with higher anti‐TNFα levels in combination therapy.

Methods

We performed a retrospective cross‐sectional multicentre study of patients with IBD on combination anti‐TNFα and thiopurine maintenance therapy between January 2015 and August 2021. Primary outcomes were infliximab and adalimumab levels. Secondary outcomes were antibodies to infliximab (ATI) or adalimumab (ATA). Univariable and multivariable linear regression were performed to identify variables associated with anti‐TNFα levels. Receiver operator characteristic curves were used to define the optimal 6‐TGN cut‐off levels associated with therapeutic anti‐TNFα levels.

Results

The study included 743 paired 6‐TGN and anti‐TNFα levels (640 infliximab and 103 adalimumab). 6‐TGN levels were associated with infliximab levels, but not adalimumab levels, on univariable and multivariable regression. The optimal 6‐TGN cut‐off associated with therapeutic infliximab levels (≥5 mcg/mL) was 261 pmol/8 × 10 8 red blood cell (RBC) (area under the curve (AUC) = 0.57) for standard infliximab dosing and 227.5 pmol/8 × 10 8 RBC (AUC = 0.58) for escalated dosing. For therapeutic adalimumab levels (≥7.5 mcg/mL), the 6‐TGN cut‐off was 218.5 pmol/8 × 10 8 RBC (AUC = 0.59) for standard adalimumab dosing and 237.5 pmol/8 × 10 8 RBC (AUC = 0.63) for escalated dosing.

Conclusion

6‐TGN levels were weakly associated with infliximab but not adalimumab levels in combination therapy. 6‐TGN levels in the lower end of the therapeutic range (230–260 pmol/8 × 10 8 RBC) may be adequate to maintain higher infliximab levels, particularly with escalated infliximab dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabDrug Therapy, CombinationInflammatory Bowel DiseasesInfliximabThionucleotidesAdultFemaleHumansMaleMiddle AgedCross-Sectional StudiesGastrointestinal AgentsGuanine NucleotidesRetrospective StudiesTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

adalimumabinflammatory bowel diseaseinfliximabtherapeutic drug monitoringthiopurines

Substanzen

6-thioguanylic acidAdalimumabGastrointestinal AgentsGuanine NucleotidesInfliximabThionucleotidesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, Austin Health, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.

ORCID-Profile: Natalie Yu, Daniel Tassone, Chamara Basnayake, Ola Niewiadomski, Michael A Kamm, Daniel Van Langenberg

Zitieren

APA

Yu, N., Lee, T., Tassone, D., Vogrin, S., Phan, S., Wu, D. M., Zhang, J., Wang, L., Tjahyadi, J., Dutt, K., Liou, H., Basnayake, C., Wright, E., Niewiadomski, O., Lust, M., Schulberg, J., Kamm, M. A., Connell, W., Thompson, A. J., …, & Ding, N. S. (2024). 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy. Internal Medicine Journal. https://doi.org/10.1111/imj.16504

Vancouver

Yu N, Lee T, Tassone D, Vogrin S, Phan S, Wu DM, et al. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy. Internal Medicine Journal. 2024. doi:10.1111/imj.16504

BibTeX
@article{Yu2024,
  author = {Yu, Natalie and Lee, Tanya and Tassone, Daniel and Vogrin, Sara and Phan, Steven and Wu, Damien M and Zhang, Jason and Wang, Luke and Tjahyadi, Jason and Dutt, Krishneel and Liou, Hana and Basnayake, Chamara and Wright, Emily and Niewiadomski, Ola and Lust, Mark and Schulberg, Julien and Kamm, Michael A and Connell, William and Thompson, Alexander J and Hilmi, Ida and Raja Ali, Raja A and Wei, Shu C and De Cruz, Peter and Friedman, Antony B and Moore, Gregory T and Van Langenberg, Daniel and Ding, Nik S},
  title = {6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16504}
}
Kostenlos starten →